Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
2.995
+0.155 (5.46%)
Nov 21, 2024, 1:37 PM EST - Market open
Repare Therapeutics Revenue
Repare Therapeutics had revenue of $66.52M in the twelve months ending September 30, 2024, up 18.19% year-over-year. In the year 2023, Repare Therapeutics had annual revenue of $51.13M, down -61.21%.
Revenue (ttm)
$66.52M
Revenue Growth
+18.19%
P/S Ratio
1.81
Revenue / Employee
$371,642
Employees
179
Market Cap
127.32M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRPTX News
- 9 days ago - Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - Business Wire
- 14 days ago - Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 4 weeks ago - Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - Business Wire
- 5 weeks ago - Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - Business Wire
- 7 weeks ago - Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - Business Wire
- 2 months ago - Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers - Business Wire
- 2 months ago - Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 - Business Wire
- 2 months ago - Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data - Seeking Alpha